Carna Biosciences, Inc.
Stock Price Chart
2026/08/03 UpdatedPrice Trend
2026/08/03 UpdatedPrice & Trading Details
2026/08/03 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF
|
4.4K | 0.00% |
Financial Performance
2026/08/02 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,387M | ¥1,626M | ¥636M | ¥579M |
| Gross Profit | ¥1,215M | ¥1,451M | ¥466M | ¥388M |
| Operating Income | -¥1,270M | -¥1,117M | -¥2,076M | -¥2,075M |
| Pretax Income | -¥1,318M | -¥1,127M | -¥2,171M | -¥2,160M |
| Net Income | -¥1,350M | -¥1,153M | -¥2,179M | -¥2,171M |
| EPS | -¥99.10 | -¥68.62 | -¥121.64 | -¥113.62 |
| Operating Margin | -91.57% | -68.70% | -326.31% | -358.34% |
| Balance Sheet | ||||
| Total Assets | ¥4,266M | ¥4,350M | ¥2,772M | ¥1,230M |
| Total Equity | ¥3,642M | ¥3,878M | ¥2,475M | ¥309M |
| Total Liabilities | ¥625M | ¥472M | ¥297M | ¥920M |
| Cash | ¥3,379M | ¥2,889M | ¥2,108M | ¥517M |
| Interest-bearing Debt | ¥300M | ¥183M | ¥61M | ¥714M |
| Equity Ratio | 85.36% | 89.14% | 89.29% | 25.15% |
| D/E Ratio | 0.08 | 0.05 | 0.02 | 2.31 |
| Cash Flow | ||||
| Operating CF | -¥708M | -¥1,677M | -¥1,375M | -¥2,159M |
| Investing CF | -¥126M | -¥11M | -¥13M | -¥25M |
| Financing CF | ¥367M | ¥1,182M | ¥567M | ¥605M |
| Free CF | -¥834M | -¥1,689M | -¥1,388M | -¥2,169M |
| Efficiency | ||||
| ROE | -37.06% | -29.73% | -88.01% | -702.25% |
| ROA | -31.63% | -26.50% | -78.59% | -176.59% |
Latest IR Information
-
docirbrutinib (AS-1763) Development-Accelerating Stock Option Plan with Exercise Price Adjustment Clause – Monthly Exercise Status
Disclosure of the July 2026 monthly exercise status for the docirbrutinib (AS-1763) development-accelerating stock option. Shares issued: 40,000 shares; rights exercised: 400 (0.51% of issued shares). Unexercised rights at month-end: 7,570,300 shares. Exercise restriction ratio: 0.20%.
Read more -
FDA Orphan Drug Designation Acquired｜Karnaby BioScience July 2026
Karnaby BioScience has obtained orphan drug designation from the U.S. FDA for monzosertib (AS-0141), advancing clinical development. Expectations are high for accelerating development and securing market exclusivity in the future.
Read more -
Notice on Monthly Exercise Status of Warrant for Accelerating Development of Docirbrutinib (AS-1763) with Exercise Price Adjustment Clause
Read more
Latest News (5 items)
Company Information
About
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.
